Key result
CVOT Summit 2021 reviews recent trials to guide diabetes and obesity management.
Answers are grounded in this paper and cite their sources.
The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18-19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year's focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1-5, and STEP 1-5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed.Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10-11, 2022 ( http://www.cvot.org ).
No takes yet. Share an insight, caveat, or question.
Schnell et al. (2022) studied Diabetes, obesity, and heart failure. The 2021 CVOT Summit reviewed recently completed cardiovascular outcome trials, including EMPEROR-Preserved and FIGARO-DKD, to discuss their implications for diabetes and obesity management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: